|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
Vaping essays: E-cigarette sellers offering scholarships [AP]
|
|
|
|
|
|
The
tactic is taken from a method that was once believed to improve a
site’s ranking in search results, and it has successfully landed vaping
brands on the sites of some of the nation’s best-known universities,
including Harvard. It also has drawn criticism that the scholarships are
a thinly disguised ploy to attract young customers.
|
|
|
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
Going further to make all clinical trials public [MRC]
|
|
|
|
|
|
The
NIH is by far the largest non-commercial funder of clinical trials in
the world and so when it changes, it changes the baseline for what a
funder could do. We hope it will show organisations who are already
doing well – like the MRC – that there is still further they can go.
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
5.2 Pharma
|
|
|
Ipsen moves U.S. headquarters to Kendall Square [FierceBiotech]
|
|
|
|
|
|
Paris-based
Ipsen established a toehold in the city in 2014 and went on to boost
its presence last year through a $1.25 billion deal with Merrimack. Now,
Ipsen is moving its U.S. headquarters from New Jersey to Kendall
Square, positioning it to add more than 200 people to its Cambridge
workforce in the years to come.
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
To all involved — we have a problem [Nature Reviews Clincal Oncology]
|
|
|
|
|
|
We
have a problem: the rising cost of anticancer therapies and the current
regulatory environment have helped to create an unsustainable (and
unacceptable) situation. This problem frequently receives attention in
our journal — and we consider that our duty is to do so. This is a call
to all stakeholders to state what their position is in face of this
problem.
|
|
|
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
Visualize: ASCO 2018’s winners and losers [EndPoints]
|
|
|
|
|
|
We
created this chart based on data compiled by EP Vantage to show you
just how influential ASCO data can be. In Roche’s case, it destroyed
$17.4 billion in market cap value. Merck’s ASCO news, however, created
$4.4 billion.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
Low-fat diet tied to improved breast cancer survival odds [Reuters]
|
|
|
|
|
|
Researchers
studied 19,541 participants in the federally funded Women’s Health
Initiative (WHI) who were randomly selected to join a dietary experiment
focused on limiting fat intake to 20 percent of calories. Researchers
also looked at data for a control group of 29,294 women in the WHI study
who didn’t alter their diets.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
The fight has begun over Europe’s big budget increase for science [Science]
|
|
|
|
|
|
European
universities are unhappy about the details, announced yesterday, of
Horizon Europe, the European Union’s new 7-year research program that
will start in 2021. They say the 22% increase in funding overall
proposed by the European Commission is the bare minimum and worry that
the program shortchanges basic research in favor of innovation funding.
|
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
STAR Act Aims to Boost Pediatric Research [Cancer Research Catalyst]
|
|
|
|
|
|
This
week, President Trump signed the Childhood Cancer Survivorship,
Treatment, Access and Research (STAR) Act, which is aimed at supporting
pediatric cancer research. The legislation calls for expanding the
collection of patient biospecimens and records, improving surveillance,
and investigating pediatric survivorship.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|